Go to page
 

Bibliographic Metadata

Title
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Na < ve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
AuthorFerenci, Peter ; Caruntu, Florin A. ; Lengyel, Gabriella ; Messinger, Diethelm ; Bakalos, Georgios ; Flisiak, Robert
Published in
Infectious Diseases and Therapy, London, 2016, Vol. 5, Issue 2, page 113-124
PublishedLondon : Springer, 2016
LanguageEnglish
Document typeJournal Article
Keywords (EN)Boceprevir / Chronic hepatitis C / Peginterferon alfa-2a / Ribavirin / Sustained virological response
ISSN2193-8229
URNurn:nbn:at:at-ubmuw:3-107 Persistent Identifier (URN)
DOI10.1007/s40121-016-0110-5 
Restriction-Information
 The work is publicly available
Files
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Na < ve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial [0.56 mb]
Links
Reference
Classification
Abstract (English)

Introduction

Boceprevir was not previously studied with peginterferon alfa-2a/ribavirin in phase III trials in treatment-naïve chronic hepatitis C patients. The international phase IIIb/IV TriCo study was, therefore, designed to evaluate boceprevir in combination with peginterferon alfa-2a/ribavirin in treatment-naïve genotype 1 patients.

Methods

A total of 165 treatment-naïve genotype 1 patients were assigned to boceprevir plus peginterferon alfa-2a/ribavirin therapy according to the label. All patients received a 4-week lead-in with peginterferon alfa-2a/ribavirin, after which boceprevir (2400 mg/day) was introduced. The total duration of treatment ranged from 28 to 48 weeks depending on the virological response at Weeks 4, 8, and 24, and on fibrosis status. The primary efficacy outcome was sustained virological response (SVR) [undetectable hepatitis C virus (HCV) ribonucleic acid (RNA) 12 weeks after actual end of treatment, SVR12].

Results

The overall SVR12 rate was 81% (133/165, 95% confidence interval 7486%). After 8 weeks of treatment, 61% of patients had undetectable HCV RNA, and 78 patients (47%) had an early response (undetectable HCV RNA at Weeks 8 and 24) and were eligible to stop all therapy at Week 28. Among early responders the SVR12 rate was 95% (74/78), and among patients with cirrhosis assigned to 48 weeks treatment, the SVR12 rate was 67% (14/21). The overall relapse rate was 7% (10/143), and was 4% (3/77) among early responders. The most common adverse events were anemia (41%), neutropenia (32%), and dysgeusia (31%).

Conclusion

High SVR12 rates can be achieved with boceprevir plus peginterferon alfa-2a/ribavirin in treatment-naïve HCV genotype 1 patients, including patients with well-compensated cirrhosis. Treatment is well tolerated when label restrictions are taken into account.

Stats
The PDF-Document has been downloaded 2 times.
License
CC-BY-NC-License (4.0)Creative Commons Attribution - NonCommercial 4.0 International License